000			01918cam a2200325 a 4500
003			EG-GiCUC
005			20250223031752.0
008			170808s2016 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aGift
097			_aM.Sc
099			_aCai01.34.M.Sc.2016.Ya.P
100	0		_aYasmine Mostafa Mohamed Ibrahim Shaalan
245	1	0	_aPhytochemicals as innovative drug leads in molecular targeted therapy of hepatocellular carcinoma / _cYasmine Mostafa Mohamed Ibrahim Shaalan ; Supervised Hend Eltayebi , Ahmed Ihab Abdelaziz , Heba Handoussa
260			_aCairo : _bYasmine Mostafa Mohamed Ibrahim Shaalan , _c2016
300			_a138 Leaves ; _c30cm
502			_aThesis (M.Sc.) - German University - Faculty of Postgraduate Studies and Scientific Research - Department of Pharmaceulical Biology
520			_aBackground: There has been an alarming increase in the burden of hepatocellular carcinoma (HCC) in Egypt. The IGF axis has emerged as one of the key players in HCC pathogenesis. IGF2BP1 and IGF2BP3 belong to family of oncogenic RNA-binding protiens, highly up-regulated in HCC. IGF2BPs influence their transcript target's fate by caging their target mRNA in cytoplasmic protein-RNA complexes, which provide a bona fide mechanism to prevent the premature decay or enhance the translation of specific target transcripts, including IGF2. Extensive evidence suggest that miRNAs play critical roles in cancer progression and specifically in regulating the IGF axis members
653		4	_aHepatocellular carcinoma
653		4	_aInnovative drug
653		4	_aMolecular targeted therapy
700	0		_aAhmed Ihab Abdelaziz , _eSupervisor
700	0		_aHeba Handoussa , _eSupervisor
700	0		_aHend Eltayebi , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c61859 _d61859